CN116082457A - 蛋白化合物及其用途 - Google Patents

蛋白化合物及其用途 Download PDF

Info

Publication number
CN116082457A
CN116082457A CN202211550292.7A CN202211550292A CN116082457A CN 116082457 A CN116082457 A CN 116082457A CN 202211550292 A CN202211550292 A CN 202211550292A CN 116082457 A CN116082457 A CN 116082457A
Authority
CN
China
Prior art keywords
amino acid
protein molecule
pkc
absent
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211550292.7A
Other languages
English (en)
Chinese (zh)
Inventor
苏达·拉奥
彼得·米尔本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Canberra
Original Assignee
University of Canberra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900314A external-priority patent/AU2016900314A0/en
Application filed by University of Canberra filed Critical University of Canberra
Publication of CN116082457A publication Critical patent/CN116082457A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202211550292.7A 2016-02-01 2017-02-01 蛋白化合物及其用途 Pending CN116082457A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2016900314 2016-02-01
AU2016900314A AU2016900314A0 (en) 2016-02-01 Proteinaceous compounds and uses therefor
PCT/AU2017/050083 WO2017132728A1 (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor
CN201780021694.9A CN108883155A (zh) 2016-02-01 2017-02-01 蛋白化合物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780021694.9A Division CN108883155A (zh) 2016-02-01 2017-02-01 蛋白化合物及其用途

Publications (1)

Publication Number Publication Date
CN116082457A true CN116082457A (zh) 2023-05-09

Family

ID=59499146

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211550292.7A Pending CN116082457A (zh) 2016-02-01 2017-02-01 蛋白化合物及其用途
CN201780021694.9A Pending CN108883155A (zh) 2016-02-01 2017-02-01 蛋白化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780021694.9A Pending CN108883155A (zh) 2016-02-01 2017-02-01 蛋白化合物及其用途

Country Status (8)

Country Link
US (1) US10487115B2 (https=)
EP (1) EP3411061A4 (https=)
JP (2) JP7341451B2 (https=)
CN (2) CN116082457A (https=)
AU (1) AU2017214761B2 (https=)
CA (1) CA3011870A1 (https=)
SG (1) SG11201806122YA (https=)
WO (1) WO2017132728A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019090390A1 (en) * 2017-11-08 2019-05-16 University Of Canberra Immunogenic compositions and uses therefor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
AUPP807899A0 (en) 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
WO2000036083A2 (en) * 1998-12-17 2000-06-22 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
AU2000265054A1 (en) 2000-07-31 2002-02-13 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
CA2489458A1 (en) 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
WO2004076654A1 (en) * 2003-02-28 2004-09-10 Novartis Ag Three-dimensional structure of the catalytic domain of protein c theta, methods and use thereof
US9592277B2 (en) 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
US11311610B2 (en) * 2010-11-01 2022-04-26 University Of Technology Sydney Immune-modulating agents and uses therefor
EP3384939A1 (en) * 2011-03-11 2018-10-10 Vib Vzw Molecules and methods for inhibition and detection of proteins
CA2885894C (en) 2012-09-27 2021-11-23 University Of British Columbia Peptide directed protein knockdown
ES2851724T3 (es) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Modulación de células madre
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor

Also Published As

Publication number Publication date
CN108883155A (zh) 2018-11-23
JP7341451B2 (ja) 2023-09-11
EP3411061A4 (en) 2019-07-10
AU2017214761A1 (en) 2018-08-02
US10487115B2 (en) 2019-11-26
JP2022023949A (ja) 2022-02-08
AU2017214761B2 (en) 2024-02-01
SG11201806122YA (en) 2018-08-30
CA3011870A1 (en) 2017-08-10
EP3411061A1 (en) 2018-12-12
US20190040103A1 (en) 2019-02-07
JP2019506167A (ja) 2019-03-07
WO2017132728A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
US9221886B2 (en) Supercharged proteins for cell penetration
TWI678374B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
CN107312759B (zh) 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
KR102071514B1 (ko) 세포-투과성 펩티드
AU2019207534B2 (en) Proteinaceous molecules and uses therefor
EP2797617B1 (en) Anti-tumor adjuvant therapy
Chen et al. Unleashing the potential of natural biological peptide Macropin: Hydrocarbon stapling for effective breast cancer treatment
CN102140473A (zh) 抗肿瘤的核酸与多肽及其应用
JP2020072716A (ja) 細胞透過組成物およびそれを用いる方法
CN116082457A (zh) 蛋白化合物及其用途
JP6654899B2 (ja) カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
CA3208598A1 (en) Novel bicyclic peptides
CN114599375B (zh) 核酸递送促进剂
US20240228543A1 (en) Cyclic peptide inhibitors of usp22
HK40109091A (zh) 核酸寡聚体及其用途
US20170066801A1 (en) Alpha3beta hydrogen bond surrogate macrocycles as modulators of ras

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination